Gene
HRAS
HRAS is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (78), Actionable biomarkers (4), Trial mentions (86), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention HRAS. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with a planned future start and 2 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 1 dated before 1990 and 5 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 13 of 8,738 | 0.15% | not measured | |
| 2025 | 7 of 8,875 | 0.08% | not measured | |
| 2024 | 4 of 8,597 | 0.05% | not measured | |
| 2023 | 12 of 8,275 | 0.15% | 26 of 11,460 | 0.23% |
| 2022 | 5 of 8,285 | 0.06% | 17 of 13,598 | 0.13% |
| 2021 | 4 of 8,692 | 0.05% | 31 of 15,045 | 0.21% |
| 2020 | 5 of 7,640 | 0.07% | 28 of 14,459 | 0.19% |
| 2019 | 5 of 7,300 | 0.07% | 32 of 12,159 | 0.26% |
| 2018 | 7 of 6,927 | 0.10% | 24 of 11,854 | 0.20% |
| 2017 | 8 of 6,558 | 0.12% | 24 of 11,595 | 0.21% |
Showing 10 of 37 years.
Assay-provider ledger (78)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Belay Diagnostics | Diagnostic provider | Clinical validationAnalytical validation | 1 | July 01, 2025 |
| ArcherDX | Unclassified | No clinical or analytical validation recorded for this pair | 1 | January 01, 2025 |
| Illumina | Unclassified | Clinical validationAnalytical validation | 5 | January 01, 2025 |
| NanoString Technologies | Unclassified | Clinical validationAnalytical validation | 2 | January 01, 2025 |
| Promega | Reagent supplier | Clinical validationAnalytical validation | 3 | January 01, 2025 |
Showing 5 of 78 assay-provider companies.
Actionable biomarkers (4)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| HRAS oncogenic mutation | Mek Inhibitor +/- Mtor Inhibitors | response-associated | acute myeloid leukemia | Cancer Genome Interpreter |
| HRAS oncogenic mutation | Pi3k Pathway Inhibitor + Mek Inhibitors | response-associated | cervical carcinoma | Cancer Genome Interpreter |
| HRAS oncogenic mutation | Mtor Inhibitors | response-associated | cervical squamous cell carcinoma | Cancer Genome Interpreter |
| HRAS oncogenic mutation | Tipifarnib | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (86)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT05365412 | Trial biospecimen (AACT) |
| NCT03452774 | Trial eligibility (AACT) |
| NCT07702032 | Trial eligibility (AACT) |
| NCT04219007 | Trial eligibility (AACT) |
| NCT03454035 | Trial eligibility (AACT) |
Showing 5 of 86 trial mentions.
Target-disease associations (488)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| ACTH-Producing Pituitary Gland Adenoma | cancer or benign tumor | Cancer Gene Census |
| ACTH-Producing Pituitary Gland Carcinoma | cancer or benign tumor | Cancer Gene Census |
| Abnormality of the cardiovascular system | phenotype | Variant curation (ClinVar / EVA) |
| Adenosquamous Carcinoma | cancer or benign tumor | Cancer Gene Census |
| Adrenal Gland Neuroblastoma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 488 associations.
Vendor sourcing (251)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic (SCV000207860, PS1). The missense variant is located in... | View ClinVar record SCV002011965.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The HRAS c.34G>T; p.Gly12Cys variant (rs104894229; ClinVar Variation ID: 12613) is reported in the literature as a recurrent de novo variant in multiple indi... | View ClinVar record SCV004562717.1 |
| Adlai Nortye Biopharma Co., Ltd. | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Aged ≥18 years old at the time of informed consent. 2. Able to provide informed consent voluntarily before any study-related activities and according t... | View trial NCT07252479 |
| Adlai Nortye Biopharma Co., Ltd. | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * 18 years old at the time of informed consent. Able to provide informed consent voluntarily before any trial-related activities and according to local g... | View trial NCT07686445 |
| Adlai Nortye Biopharma Co., Ltd. | Trial sponsor | Mentioned in trial textTrial free-text mention | HRAS | View trial NCT07686445 |
Showing 5 of 251 sourcing records.
Trial-cited literature (359)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | 13 |
| Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. | Nature | 2024 | 302 |
| Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. | Nature medicine | 2024 | 122 |
| Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. | JAMA oncology | 2024 | 61 |
| Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation. | The Journal of clinical investigation | 2024 | 47 |
Showing 5 of 359 papers.
Protein variant mentions (28)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A11T | 1 | 2015 | PMID 25741868 |
| p.A121T | 1 | 2015 | PMID 25741868 |
| p.A130P | 1 | 2015 | PMID 25741868 |
| p.A146T | 1 | 2016 | PMID 26619011 |
| p.A146V | 1 | 2016 | PMID 26619011 |
Showing 5 of 28 variants.
Literature-extracted relations (49)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Vemurafenib | Chemical | positive_correlate |
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. | 2012 |
| SIMVASTATIN | Chemical | negative_correlate |
Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling. | 2006 |
| Neoplasms | Disease | associate |
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. | 2024 |
| Squamous Cell Carcinoma of Head and Neck | Disease | associate |
The mutational spectrum in whole exon of p53 in oral squamous cell carcinoma and its clinical implications. | 2022 |
| Pheochromocytoma | Disease | associate |
New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications. | 2022 |
Showing 5 of 49 relation assertions.
Organizations publishing (339)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 32 | 1997 to 2022 |
| Memorial Sloan Kettering Cancer Center | Hospital | 24 | 2005 to 2024 |
| Dana-Farber Cancer Institute | Other | 16 | 2014 to 2024 |
| The University of Texas System | Academic | 16 | 2010 to 2023 |
| Harvard Medical School | Academic | 12 | 1993 to 2025 |
Showing 5 of 339 organizations.
Where HRAS appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
382 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.